Skip to main content
. Author manuscript; available in PMC: 2011 Jun 15.
Published in final edited form as: Prostate. 2010 Jun 15;70(9):1020–1035. doi: 10.1002/pros.21137

Table 4.

Prostate cancer risk associated with serum cav-1 levels, by disease aggressivenessa,b

 Cav-1
  measure		 Controls
(n=226)		 Less Aggressive
(n=93)		 ORc 95% CI More Aggressive
(n=109)		 ORc 95% CI ptrend
Mean (SD) Median Mean (SD) Median Mean (SD) Median
Cav-1 3.36 (7.27) 0.69 3.71 (6.22) 0.81 1.01 0.97 1.04 2.91 (6.70) 0.85 0.99 0.96 1.03 0.76
Ln of cav-1 −0.27 (1.86) −0.38 0.08 (1.75) −0.21 1.11 0.97 1.28 −0.26 (1.77) −0.17 1.00 0.88 1.14 0.27
 n (%)  n (%) OR 95% CI  n (%) OR 95% CI p
Low cav-1 34 (15.0) 10 (10.8) 1.00 Ref  96 (88.1) 1.00 Ref 0.37
High cav-1d 192 (85.0) 83 (89.3) 1.29 0.79 2.10 13 (11.9) 1.34 0.84 2.12
 n (%)  n (%) OR 95% CI  n (%) OR 95% CI p
Lowest 45 (19.9) 12 (12.9) 1.00 Ref 16 (14.7) 1.00 Ref 0.36
2nd 45 (19.9) 21 (22.6) 1.76 0.77 4.02 22 (20.2) 1.33 0.62 2.87
3rd 45 (19.9) 22 (23.7) 1.84 0.81 4.18 24 (22.0) 1.46 0.68 3.12
4th 46 (20.4) 15 (16.1) 1.24 0.52 2.94 31 (28.4) 1.83 0.88 3.81
Highest 45 (19.9) 23 (24.7) 1.91 0.85 4.31 16 (14.7) 0.99 0.44 2.22

OR=odds ratio, adjusted for age at diagnosis/reference date; SD=standard deviation; CI=confidence interval

a

Caucasians only.

b

More aggressive PC is defined as regional or distant stage, or Gleason score 7 (4+3) or 8–10, or diagnostic PSA ≥20 ng/ml.

c

OR given a one unit (ng/ml) increase in cav-1 or the natural log of cav-1, respectively.

d

High cav-1 is defined by the median level among controls (0.69 ng/ml).